Literature DB >> 19364855

Comparison of tigecycline and vancomycin for treatment of experimental foreign-body infection due to methicillin-resistant Staphylococcus aureus.

Pierre Vaudaux1, Bénédicte Fleury, Asllan Gjinovci, Elzbieta Huggler, Manuela Tangomo-Bento, Daniel P Lew.   

Abstract

Twice-daily 7-day regimens of tigecycline (7 mg/kg) and vancomycin (50 mg/kg) were compared in a rat tissue cage model of chronic foreign-body infection due to methicillin (meticillin)-resistant Staphylococcus aureus strain MRGR3. Subcutaneously administered tigecycline reached levels in tissue cage fluid that were nearly equivalent or slightly superior to the antibiotic MIC (0.5 microg/ml) for strain MRGR3. After 7 days, equivalent, significant reductions in bacterial counts were recorded for tigecycline-treated and vancomycin-treated rats, compared with those for untreated animals.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19364855      PMCID： PMC2704643          DOI： 10.1128/AAC.01612-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  38 in total

1.  Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.

Authors:  Pierre Vaudaux; Asllan Gjinovci; Manuela Bento; Dongmei Li; Jacques Schrenzel; Daniel P Lew
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

2.  Phenotypic antibiotic tolerance of Staphylococcus aureus in implant-related infections: relationship with in vitro colonization of artificial surfaces.

Authors:  P Vaudaux
Journal:  Drug Resist Updat       Date:  1998       Impact factor: 18.500

3.  Functional, biophysical, and structural bases for antibacterial activity of tigecycline.

Authors:  Matthew W Olson; Alexey Ruzin; Eric Feyfant; Thomas S Rush; John O'Connell; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

4.  Effect of medium type, age and aeration on the MICs of tigecycline and classical tetracyclines.

Authors:  R Hope; M Warner; S Mushtaq; M E Ward; T Parsons; D M Livermore
Journal:  J Antimicrob Chemother       Date:  2005-11-12       Impact factor: 5.790

Review 5.  Tigecycline: a novel glycylcycline.

Authors:  Ethan Rubinstein; David Vaughan
Journal:  Drugs       Date:  2005       Impact factor: 9.546

6.  A novel MATE family efflux pump contributes to the reduced susceptibility of laboratory-derived Staphylococcus aureus mutants to tigecycline.

Authors:  Fionnuala McAleese; Peter Petersen; Alexey Ruzin; Paul M Dunman; Ellen Murphy; Steven J Projan; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

Review 7.  Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance.

Authors:  K Hiramatsu
Journal:  Lancet Infect Dis       Date:  2001-10       Impact factor: 25.071

8.  Comparative efficacy of daptomycin and vancomycin in the therapy of experimental foreign body infection due to Staphylococcus aureus.

Authors:  Pierre Vaudaux; Patrice Francois; Carmelo Bisognano; Dongmei Li; Daniel P Lew; Jacques Schrenzel
Journal:  J Antimicrob Chemother       Date:  2003-05-29       Impact factor: 5.790

9.  Teicoplanin alone or combined with rifampin compared with vancomycin for prophylaxis and treatment of experimental foreign body infection by methicillin-resistant Staphylococcus aureus.

Authors:  H J Schaad; C Chuard; P Vaudaux; F A Waldvogel; D P Lew
Journal:  Antimicrob Agents Chemother       Date:  1994-08       Impact factor: 5.191

10.  Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.

Authors:  Jared L Crandon; Mary Anne Banevicius; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2008-12-29       Impact factor: 5.191
View more
  4 in total

1.  Effectiveness of a Glycylcycline Antibiotic for Reducing the Pathogenicity of Superantigen-Producing Methicillin-Resistant Staphylococcus aureus in Burn Wounds.

Authors:  Lauren B Nosanov; Daniel Y Jo; Pranay R Randad; Lauren T Moffatt; Bonnie C Carney; Rachel T Ortiz; Jeffrey W Shupp
Journal:  Eplasty       Date:  2017-09-07

2.  Clinical Experience with Tigecycline in the Treatment of Prosthetic Joint Infections.

Authors:  Allison Lastinger; Nathanael McLeod; Matthew J Dietz; John Guilfoose; Arif R Sarwari
Journal:  J Bone Jt Infect       Date:  2019-05-21

3.  Spontaneous Knee Hemarthrosis Due to Hypofibrinogenemia Following Tigecycline Treatment for Periprosthetic Joint Infection.

Authors:  Theodore Balfousias; Alexandros P Apostolopoulos; Stavros Angelis; Spyridon Maris; Athanasios Papanikolaou
Journal:  Cureus       Date:  2019-10-10

Review 4.  Foreign Body Infection Models to Study Host-Pathogen Response and Antimicrobial Tolerance of Bacterial Biofilm.

Authors:  Justyna Nowakowska; Regine Landmann; Nina Khanna
Journal:  Antibiotics (Basel)       Date:  2014-08-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.